Aziridine-2,3-dicarboxylic acid derivatives as inhibitors of papain

Archiv der Pharmazie

Volumn 329, Issue 5, 1996, Pages 239-244

  Schirmeister, Tanja ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

aziridine 2,3 dicarboxylic acid derivatives; irreversible cysteine protease inhibitors; papain

Indexed keywords

2,3 AZIRIDINEDICARBOXYLIC ACID DERIVATIVE; ENZYME INHIBITOR; PAPAIN; PAPAIN INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; ENANTIOMER; ENZYME BINDING; ENZYME INHIBITION; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

EID: 0029948116     PISSN: 03656233     EISSN: None     Source Type: Journal    
DOI: 10.1002/ardp.19963290504     Document Type: Article

References (78)

1. a) I. Sohar, A. Laszlo, K. Gaal, F. Mechler, Biol. Chem. Hoppe-Seyler 1988, 369, Suppl., 277-280;
2. b) S. Kawashima, M. Nakamura, M. Hayashi, ibid. 1990, 371, Suppl., 205-210;
3. c) N. Katunuma, E. Kominami in Cysteine proteinases and their Inhibitors (Ed.: V. Turk), de Gryter, Berlin, New York, 1986, 219-228.
4. a) B. Lenarcic, D. Gabrijelcic, B. Rozman, D. Drobnic-Kosorok, V. Turk, Biol. Chem. Hoppe-Seyler 1988, 369, Suppl., 257-262;
5. b) R. Maciewicz, R.-J. Wardale, S. Wotton, V. Duance, D. Etherington, ibid. 1990, 371, 223-228;
6. c) C. van Noorden, R. Smith, D. Rasnick, J. Rheumatol. 1993, 15, 1525-1535;
7. d) R. Maciewicz, S. Wotton, D. Etherington, V. Duance, FEBS Lett. 1990, 269, 189-193;
8. e) A. Page, A. Hayman, L. Andersson, T. Chambers, M. Warburton, Int. J. Biochem. 1993, 25, 545-550.
9. R. Bolli, R. Cannon, E. Speir, R. Goldstein, S. Epstein, J. Am. Coll. Cardiol. 1983, 2, 681-688.
10. a) J. Henkin, Ann. Rep. Med. Chem. 1993, 28, 151-160;
11. b) J. van der Stappen, C. Paraskeva, A. Williams, A. Hague, R. Maciewicz, Biochem. Soc. Trans. 1991, 19, 362S;
12. c) B. Casali, C. Passerini, A. Falanga, G. Fossati, N. Semeraro, M. Donati, S. Gordon in Cysteine proteinases and their Inhibitors (Ed.: V. Turk), de Gryter, Berlin, New York, 1986, 163-178;
13. d) B. Sloane, J. Rozhin, D. Robinson, K. Honn, Biol. Chem. Hoppe-Seyler 1990, 371, Suppl., 193-198;
14. e) M. Duffy, Clin. Exp. Metastasis 1992, 10, 145-155.
15. a) Proteases and Protease Inhibitors in Alzheimers Disease Pathogenesis, Ann. N. Y. Acad. Sci. 1992, 674, Eds.: C. Banner, R. Nixon;
16. b) K. Saito, J. Alce, J. Hamos, R. Nixon, Proc. Nalt. Acad. Sci. U.S.A. 1993, 90, 2628-2632.
17. a) L. David, T. Shearer, M. Shin, J. Biol. Chem. 1993, 268, 1937-1940;
18. b) Drugs Fut. 1994, 19, 1039-1040.
19. a) Drugs Fut. 1986, 11, 927-930;
20. b) ibid. 1990, 15, 1128;
21. c) ibid. 1991, 16, 1040;
22. d) R. Esser, R. Angelo, M. Murphey, L. Watts, L. Thornburg, J. Palmer, J. Talhouk, R. Smith, Arthritis Rheumatism 1994, 37, 236-247;
23. e) N. Ahmed, L. Martin, L. Watts, J. Palmer, L. Thornburg, J. Prior, R. Esser, Biochem. Pharmacol. 1993, 44, 1201-1207.
24. a) R. Mitchell, I. Chaiken, E. Smith, J. Biol. Chem. 1970, 245, 3485-3492;
25. b) J. Drenth, J. Jansonius, R. Koekoek, B. Wolters in The Enzymes (Ed.: P. Boyer), Academic Press, N.Y., London, 1971, 3, 485-499;
26. c) G. Lowe, Tetrahedron 1976, 32, 291-302;
27. d) K. Varughese, F. Ahmed, P. Carey, S. Hasnain, C. Huber, A. Storer, Biochemistry 1989, 28, 1330-1332.
28. N. Rawlings, A. Barrett, Meth. Enzymol. 1994, 244, 461-486.
29. Examples of irreversible inhibitors are: a) peptidyl chloro methyl ketones: J. Drenth, K. Kalk, H. Swen, Biochemistry 1976, 15, 3731-3738; b) diazo methyl ketones: G. Green, E. Shaw, J. Biol. Chem. 1981, 256, 1923-1928; c) acyloxy methyl ketones: A. Krantz, L. Copp, P. Cotes, R. Smith, S. Heard, Biochemistry 1991, 30, 4678-4687; d) O-acyl hydroxamates: D. Brömme, A. Schierhorn, H. Kirschke, B. Wiederanders, A. Barth, S. Fittkau, H.-U. Demuth, Biochem. J. 1989, 263, 861-866.
30. Examples of irreversible inhibitors are: a) peptidyl chloro methyl ketones: J. Drenth, K. Kalk, H. Swen, Biochemistry 1976, 15, 3731-3738; b) diazo methyl ketones: G. Green, E. Shaw, J. Biol. Chem. 1981, 256, 1923-1928; c) acyloxy methyl ketones: A. Krantz, L. Copp, P. Cotes, R. Smith, S. Heard, Biochemistry 1991, 30, 4678-4687; d) O-acyl hydroxamates: D. Brömme, A. Schierhorn, H. Kirschke, B. Wiederanders, A. Barth, S. Fittkau, H.-U. Demuth, Biochem. J. 1989, 263, 861-866.
31. Examples of irreversible inhibitors are: a) peptidyl chloro methyl ketones: J. Drenth, K. Kalk, H. Swen, Biochemistry 1976, 15, 3731-3738; b) diazo methyl ketones: G. Green, E. Shaw, J. Biol. Chem. 1981, 256, 1923-1928; c) acyloxy methyl ketones: A. Krantz, L. Copp, P. Cotes, R. Smith, S. Heard, Biochemistry 1991, 30, 4678-4687; d) O-acyl hydroxamates: D. Brömme, A. Schierhorn, H. Kirschke, B. Wiederanders, A. Barth, S. Fittkau, H.-U. Demuth, Biochem. J. 1989, 263, 861-866.
32. Examples of irreversible inhibitors are: a) peptidyl chloro methyl ketones: J. Drenth, K. Kalk, H. Swen, Biochemistry 1976, 15, 3731-3738; b) diazo methyl ketones: G. Green, E. Shaw, J. Biol. Chem. 1981, 256, 1923-1928; c) acyloxy methyl ketones: A. Krantz, L. Copp, P. Cotes, R. Smith, S. Heard, Biochemistry 1991, 30, 4678-4687; d) O-acyl hydroxamates: D. Brömme, A. Schierhorn, H. Kirschke, B. Wiederanders, A. Barth, S. Fittkau, H.-U. Demuth, Biochem. J. 1989, 263, 861-866.
33. K. Hanada, M. Tamai, M. Yamagishi, S. Ohmura, J. Sawada, I. Tanaka, Agric. Biol. Chem. 1978, 42, 523-528.
34. ref. 6b); ref. 7a).
35. a) K. Varughese, F. Ahmed, P. Carey, S. Hasnain, C. Huber, A. Storer, Biochemistry 1989, 28, 1330-1332;
36. b) Y. Yabe, D. Guillaume, D. Rich, J. Am. Chem. Soc. 1988, 110, 4043-4044;
37. c) K. Matsumoto, D. Yamamoto, H. Ohishi, K. Tomoo, T. Ishida, M. Inoue, T. Sadatome, K. Kitamura, H. Mizuno, FEBS Lett. 1989, 245, 177-180.
38. a) T. Noda, K. Isogal, N. Katunuma, Y. Tarumoto, M. Ohzeki, J. Biochem. 1981, 90, 893-896;
39. b) M. Tamai, K. Matsumoto, S. Omura, I. Koyama, Y. Ozawa, K. Hanada, J. Pharmacobio-Dyn. 1986, 9, 672-677.
40. a) A. Barrett, A. Kembhavi, M. Brown, H. Kirschke, C. Knight, M. Tamai, K. Hanada, Biochem. J. 1982, 201, 189-198;
41. b) B. Gour-Salin, P. Lachance, C. Plouffe, A. Storer, R. Menard, J. Med. Chem. 1993, 36, 720-725;
42. c) M. Murata, S. Miyashita, C. Yokoo, M. Tamai, K. Hanada, K. Hatayama, T. Towatari, T. Nikawa, N. Katunuma, FEBS Lett. 1991, 280, 307-310;
43. d) M. Tamai, T. Adachi, K. Oguma, S. Morimoto, K. Hanada, S. Ohmura, M. Ohzeki, Agric. Biol. Chem. 1981, 45, 675-679;
44. e) M. Tamai, K. Hanada, T. Adachi, K. Oguma, K. Kashiwagi, S. Ohmura, M. Ohzeki, J. Biochem. 1981, 90, 255-257;
45. f) Z. Huang, E. McGowan, T. Detwiler, J. Med. Chem. 1992, 35, 2048-2054;
46. g) B. Gour-Salin, P. Lachance, P. Bonneau, A. Storer, H. Kirschke, D. Brömme, Bioorg. Chem. 1994, 22, 227-241.
47. a) K. Okawa, K. Nakajima, Biopolymers 1981, 20, 1811-1821;
48. b) Y. Hata, M. Watanabe, Tetrahedron 1987, 43, 3881-3888.
49. a) L. Moroder, H.-J. Musiol, R. Scharf, FEBS Lett. 1992, 299, 51-53;
50. b) A. Korn, S. Rudolph, L. Moroder, Tetrahedron 1994, 50, 1717-1730;
51. c) M. Yamamoto, J. Powers, T. Tachibana, K. Egusa, K. Okawa, Peptide Chemistry 1993, 189-192.
52. ref. 15a).
53. N. Furukawa, S. Oae, Synthesis 1976, 1, 30-32.
54. a) K. Mori, H. Iwasawa, Tetrahedron 1980, 36, 87-90;
55. b) A. Korn, S. Rudolph-Böhner, L. Moroder, Tetrahedron 1994, 50, 8381-8392;
56. c) E. Corey, P. Lansbury Jr., J. Am. Chem. Soc. 1983, 105, 4093-4094.
57. J. Legters, L. Thijs, B. Zwanenburg, Tetrahedron 1991, 47, 5287-5294.
58. R. Kitz, I. Wilson, J. Biol. Chem. 1962, 237, 3245-3249.
59. a) H. Bisswanger, Enzymkinetik - Theorie und Methoden, VCH, Weinheim, 1994, 2. Aufl., 126-129;
60. b) C. Knight in Proteinase Inhibitors (Eds.: A. Barrett, G. Salvesen), Elsevier, Amsterdam, 1986, chapter 2, 42-44.
61. B. Anderson, E. Vasini, Biochemistry 1970, 9, 3348-3352.
62. K. Hanada, M. Tamai, S. Morimoto, T. Adachi, S. Ohmura, J. Sawada, I. Tanaka, Agric. Biol. Chem. 1978, 42, 537-541.
63. K. Brocklehurst, F. Willenbrock, E. Salih in New Comprehensive Biochemistry (Eds.: A. Neuberger, K. Brocklehurst), Elsevier, Amsterdam, 1987, Vol. 16, 39-158.
64. R. Dolle, D. Hoyer, C. Prasad, S. Schmidt, C. Helaszek, R. Miller, M. Ator, J. Med. Chem. 1994, 37, 563-564.
65. M. Bucciarelli, A. Forni, I. Moretti, F. Prati, G. Torre, J. Chem. Soc. Perkin Trans. 1 1993, 3041-3045.
66. G. Wendlberger in Houben-Weyl, Methoden der organischen Chemie, Synthese von Peptiden (Ed.: E. Wünsch), Vol. 15/II, 4. Aufl., Thieme Verlag, Stuttgart, 1974, 55-58.
67. a) H. Tuppy, U. Wiesbauer, Hoppe Seyler's Zeitschr. Physiol. Chem. 1962, 329, 278-288;
68. b) G. Sarath, R. de la Motte, F. Wagner in Proteolytic Enzymes (Ed.: R. Beynon), IRL Press, Oxford, 1989, 25-55;
69. c) R. Arnon in Methods Enzymol. 1970, 19, 226-244;
70. d) J. Magrath, R. Abeles, J. Med. Chem. 1992, 35, 4279-4283;
71. e) L. Hu, R. Abeles, Arch. Biochem. Biophys. 1990, 281, 271-274.
72. DMS UV-Atlas organischer Verbindungen (Eds.: H. Perkampus, I. Sandemann, C. Timmons), Verlag Chemie, Weinheim, 1971, Vol. 5, spectrum D 9/60.
73. m = 2.4 mM: H. Fritz, F. Woitinas, E. Werle, Hoppe Seyler's Zeitschr. Physiol. Chem. 1966, 345, 168-180;
74. m = 2.95 mM: J. Mole, H. Horton, Biochemistry 1973, 12, 816-822;
75. m = 2.95 mM: B. Evans, J. Knopp, H. Horton, Arch. Biochem. Biophys. 1981, 206, 362-371.
76. R, Version 3.0, Erithacus Software Ltd., London, 1992.
77. a) A. Barrett, H. Kirschke in Methods Enzymol. 1981, 80, 535-565;
78. b) G. Salvesen, H. Nagase in Proteolytic Enzymes (Ed.: R. Beynon), IRL Press, Oxford, 1989, 83-104.